NASDAQ · Biotechnology

Dare Bioscience, Inc. (DARE) Stock

$0.77 +0.16% NASDAQ: DARE Healthcare

Valuation

MetricValue
Price$0.77
Market Cap$11.59M
P/E Ratio-0.98
P/B Ratio-20.53
P/S Ratio8.47
EPS (TTM)$0.00
52-Week High$3.78
52-Week Low$0.69
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-748.08%
ROA-49.12%
ROCE-203.95%
Gross Margin-1400.00%
Operating Margin-1400.00%
Net Margin-804.37%
Debt/Equity-12.08
Current Ratio1.13

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$10.0M$3.0M$0$1.0M
Operating Profit$-39.0M$-31.0M$-31.0M$-23.0M$-14.0M
Net Profit$-39.0M$-31.0M$-30.0M$-4.0M$-13.0M
EPS$-7.52$-4.39$-4.15$-0.48$-1.20
Op Margin—-313.9%-1101.9%-239692.2%-1315.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$56.0M$44.0M$21.0M$22.0M$32.0M
Total Liabilities$17.0M$33.0M$26.0M$28.0M$30.0M
Cash$52.0M$35.0M$10.0M$16.0M$25.0M
Borrowings$0$0$1.0M$1.0M$3.0M

Latest News

Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities GlobeNewswire · Jul 20, 2026 Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event GlobeNewswire · Jul 9, 2026 Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform GlobeNewswire · Jul 1, 2026 Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment GlobeNewswire · Jun 25, 2026 Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026 GlobeNewswire · Jun 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-29.0M$-18.0M$-39.0M$5.0M$-10.0M
Investing Cash Flow$0$0$-1.0M$-1.0M$-1.0M
Financing Cash Flow$1.0M$0$6.0M$0$-1.0M
Net Cash Flow$47.0M$-17.0M$-24.0M$5.0M$9.0M
Free Cash Flow$-29.0M$-18.0M$-39.0M$5.0M$-10.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-0.66
FCF Yield-101.62%
Quick Ratio0.99
Interest Coverage-55.72
Return 1Y-27.11%
Return 3Y-80.17%
Return 5Y-88.27%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADTX $0.01 -77.22% -0.01 $318 0.00%
AIMDAinos, Inc. $1.21 +0.00% -0.54 $8.91M 0.00%
ANLAdlai Nortye Ltd. $13.26 +2.00% -8.19 $703.84M 0.00%
ASBPAspire-Lakewood Holdings, Inc. $8.30 +0.00% -1.09 $957588 0.00%
ATHAAthira Pharma, Inc. $6.75 -6.12% -0.28 $26.62M 0.00%

About Dare Bioscience, Inc.

Dare Bioscience, Inc. is led by CEO Sabrina Martucci Johnson, employs 21 people, headquartered in US, publicly traded since 2014.

Dare Bioscience, Inc. (DARE) stock trades at $0.77 with a market capitalization of $11.59M. The stock is valued at a price-to-earnings (P/E) ratio of -0.98, price-to-book of -20.53, price-to-sales of 8.47. Over the past 52 weeks the stock has ranged between $0.69 and $3.78, and currently trades 79.6% below its 52-week high.

On profitability, Dare Bioscience, Inc. generates a return on equity (ROE) of -748.08%, return on capital employed of -203.95%, an operating margin of -1400.00%, a net profit margin of -804.37%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides